The cascade of events that leads to the development of ovarian hyperstimulation syndrome (OHSS) is almost always accompanied by elevated estradiol (E(2)) levels. The role of estrogen level in OHSS has not been confirmed; however, it was shown repeatedly in the literature that elevated levels of E(2) constitute a risk for OHSS. Monitoring E(2) was found to be effective in reducing the incidence ...

Ovarian mutilating surgery is not an option in the management of ovarian hyperstimulation syndrome (OHSS), except in cases with evident tissue necrosis after torsion. When severe OHSS occurs, preservation of fertility must be the target. Therefore, conservative management should be the only feasible approach, as recommended in literature worldwide. Individualization of controlled ovarian hypers...

BACKGROUND Since severe ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication of assisted reproduction, the focus of attention in such cases is placed firmly upon the health of the patient, with the endeavour to achieve a pregnancy being considered of secondary importance. The aim of this study was to focus on the pregnancy rate and pregnancy outcome in IVF pat...

Ovarian hyperstimulation syndrome (OHSS) is still a severe complication due to controlled ovarian stimulation for artificial reproductive technology. Even though multiple techniques to avoid OHSS have been discussed in the last decades, up to now no clear concepts for primary and secondary prevention exist. This review gives an overview over proposed strategies to avoid OHSS. In a retrospective...

Introduction: Gonadotropin-releasing hormone (GnRH) agonist triggers are increasingly used in antagonist vitro fertilization (IVF) cycles to prevent ovarian hyperstimulation syndrome (OHSS) following a robust response. The luteolytic effects of GnRH agonists inhibit implantation or spontaneous pregnancy, warranting freezing available blastocysts for future transfer after the risk OHSS subsides....

Ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication of pharmacological ovarian stimulation. It is seen in approximately 2 % of all IVF cycles. The prevalence of moderate to severe OHSS ranges from 1 to 10 % in major IVF programs. Severe forms complicate 1 % of IVF cycles and are characterized by massive ovarian enlargement together with a fluid shift into ext...

Type 2 receptors for vascular endothelial growth factor are believed to be involved in the pathophysiology of ovarian hyperstimulation syndrome (OHSS). The objective of this study was to examine the preventive effects of cabergoline on OHSS and its complications. The study is a non randomized clinical trial conducted in 2006-2008 on 75 patients, which were at risk of OHSS and underwent assisted...

Consequences of stimulation of the ovaries include the serious and potentially life-threatening condition of ovarian hyperstimulation syndrome (OHSS). This can occur with any type of ovulation induction or superovulation therapy for assisted conception procedures. The development of OHSS can be reduced by the cautious use of preparations, careful monitoring of stimulation cycles, and prediction...

BACKGROUND Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of IVF/ICSI therapy. The pathophysiology and etiology of the disease is still not fully clarified. METHODS To assess whether polymorphisms of the VEGF/VEGF-receptor system contribute to the occurrence of ovarian hyperstimulation syndrome (OHSS), we performed a retrospective analysis of 116 OHSS patients, and ...

Background: Ovarian hyperstimulation syndrome (OHSS) is a rare iatrogenic complication of ovulation stimulation. The pathogenesis of OHSS is uncertain. The crucial event appears to be an increase in capillary permeability by vasoactive mediators such as cytokine and histamine. The aim of this study is to evaluate the role of loratadine (antihistamine) in preventing ovarian hyperstimulation synd...